Does rivastigmine improve cognitive functions or disability in patients with Alzheimer's disease?
Teresa Anna
TA
Cantisani
Maria Grazia
MG
Celani
Enrico
E
Righetti
D000368:Aged; D000544:Alzheimer Disease / Q000150:complications* / Q000188:drug therapy*; D002219:Carbamates / Q000494:pharmacology* / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology*; D006233:Persons with Disabilities / Q000523:psychology*; D006801:Humans; D008609:Mental Status Schedule; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D048448:Phenylcarbamates; D016032:Randomized Controlled Trials as Topic; D000068836:Rivastigmine; D016896:Treatment Outcome
D002219:Carbamates; D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D000068836:Rivastigmine